BME:ROVIPharmaceuticals
Rovi (BME:ROVI) Margin Strength In Q4 EPS Beat Tests Bearish CDMO Narrative
Laboratorios Farmaceuticos Rovi (BME:ROVI) has capped FY 2025 with fourth quarter revenue of €218.4 million and basic EPS of €0.83, while trailing 12 month figures show revenue of €743.5 million and EPS of €2.75 alongside net income of €140.4 million. The company has seen quarterly revenue move from €199.1 million in Q4 2024 to €218.4 million in Q4 2025, with net income rising over the same period from €23.4 million to €42.7 million, setting up a story where margins and earnings power sit...